BioGaia’s Probiotic Effective in Infantile Colic, Review Confirms
03 May 2016 --- A new systematic review has further strengthened the effect of BioGaia’s L. reuteri Protectis probiotic on infantile colic.
The review is the eighth meta-analysis evaluating L. reuteri Protectis’ effect on infantile colic.
Prior to the new review, seven meta-analyses – evaluating different probiotics as well as non-probiotic treatments – have come to the same conclusion: that L. reuteri Protectis is effective in reducing crying time in colicky infants, especially in breastfed and mixed fed infants.
BioGaia is an innovative Swedish health care company and a leader in probiotic production. Their products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects.
Colic is a common condition during infancy with few therapeutic options.
The new, eighth review, has four studies on L. reuteri Protectis included, the proof was further strengthened. It combined raw data from these trials (Individual Participant Data Meta-Analysis, IPDMA), a method that yields more reliable estimates of treatment effect compared to traditional meta-analyses based on published data only. The analysis was undertaken according to the methods recommended by Cochrane.
"A meta-analysis is considered the highest level of evidence of a health effect and now there are eight such meta-analyses with BioGaia ProTectis. While this clearly confirms BioGaia ProTectis as the number one treatment for infants with colic, it also reassures health care professionals around the world that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients”, said Axel Sjöblad, Managing Director of BioGaia.
The systematic review and meta-analysis was presented at the PAS (Pediatric Academic Societies) meeting in Baltimore, USA.
